AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10511436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7741291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean skin temperature maintained near 31, 34, 35, 36, and 37 degrees C in men; 31, 35, and 37 degrees C in women.
Number of subjects: 12
Study 8252269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Number of subjects: 61
Study 8252269 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 61
Study 3546144 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus piperacillin plus trimethoprim/sulphamethoxazole
Number of subjects: 161
Study 3546144 — intervention group
Group type: COMPARATOR
Intervention: Amikacin plus piperacillin
Number of subjects: 161
Study 30670642 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (dopamine precursor)
Number of subjects: 27
Study 30670642 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (dopamine antagonist)
Number of subjects: 27
Study 30670642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 27
Study 29750651 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (LA Depot) every 3 months for up to 42 months
Number of subjects: 71
Study 29750651 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (LA Depot)
Number of subjects: 71
Study 27026148 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402
Number of subjects: 20
Study 27026148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24989920 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative embolization
Number of subjects: 68
Study 24989920 — intervention group
Group type: COMPARATOR
Intervention: Conventional tumor resection
Number of subjects: 68
Study 22152978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (10 sessions)
Number of subjects: 27
Study 22152978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 27
Study 20557406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual peer review intervention
Number of subjects: 100
Study 20557406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 20557406 — intervention group
Group type: EXPERIMENTAL
Intervention: Change diaries used to record progress
Number of subjects: 100
Study 18686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated fiber post (DT Light Post)
Number of subjects: 345
Study 18686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized fiber post (Ever Stick Post)
Number of subjects: 345
Study 18686771 — intervention group
Group type: COMPARATOR
Intervention: No root canal retention
Number of subjects: 345
Study 18686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth retaining one coronal wall
Number of subjects: 345
Study 18686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth retaining two coronal walls
Number of subjects: 345
Study 18686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth retaining three coronal walls
Number of subjects: 345
Study 18686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth missing all coronal walls
Number of subjects: 345
Study 16044962 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + HCFU (300 mg/day orally for one year)
Number of subjects: 501
Study 16044962 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + UFT (300 mg/day or 400 mg/day orally for one year)
Number of subjects: 501
Study 12644340 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy (coronary angiography and revascularization when feasible) with tirofiban (for 48 h) plus aspirin and heparin
Number of subjects: 0
Study 12644340 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (angiography only for patients with recurrent ischemia at rest or a positive stress test) with tirofiban (for 48 h) plus aspirin and heparin
Number of subjects: 0
Study 9640159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine 1.0 ml kg‐1
Number of subjects: 60
Study 9640159 — intervention group
Group type: COMPARATOR
Intervention: 0.375% bupivacaine 1.0 ml kg‐1
Number of subjects: 60
Study 7914845 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 0
Study 7914845 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 7914845 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 3067954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 15
Study 3067954 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-and-sex-matched)
Number of subjects: 15
Study 30292242 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of decision aids (15 consultations)
Number of subjects: 36
Study 30292242 — intervention group
Group type: COMPARATOR
Intervention: Usual care (21 consultations)
Number of subjects: 36
Study 30292242 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient involvement
Number of subjects: 36
Study 28264588 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐Learning Plus communication partner training (CPT) programme
Number of subjects: 48
Study 28264588 — intervention group
Group type: COMPARATOR
Intervention: Supported Conversation for Adults with Aphasia (SCATM) CPT programme
Number of subjects: 48
Study 23572471 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-cultural concept for alcohol prevention
Number of subjects: 176
Study 23572471 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study 24180628 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Timolol 0.5% (Brinz/Tim)
Number of subjects: 114
Study 24180628 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2%/Timolol 0.5% (Dorz/Tim)
Number of subjects: 114
Study 21429992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 883
Study 21429992 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 883
Study 18808424 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam therapy
Number of subjects: 21
Study 16929703 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with BECTS
Number of subjects: 26
Study 16929703 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy children
Number of subjects: 26
Study 12923822 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 12923822 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 12923822 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 11137250 — intervention group
Group type: EXPERIMENTAL
Intervention: AlPO(4)‐adjuvated vaccine/2+1 schedule
Number of subjects: 134
Study 11137250 — intervention group
Group type: EXPERIMENTAL
Intervention: AlPO(4)‐adjuvated vaccine/3+1 schedule
Number of subjects: 134
Study 11137250 — intervention group
Group type: EXPERIMENTAL
Intervention: Al(OH)(3)‐adjuvated vaccine/2+1 schedule
Number of subjects: 134
Study 11137250 — intervention group
Group type: EXPERIMENTAL
Intervention: Al(OH)(3)‐adjuvated vaccine/3+1 schedule
Number of subjects: 134
Study 9085953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.04 mg/mL
Number of subjects: 78
Study 9085953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.02 mg/mL
Number of subjects: 78
Study 9085953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.08 mg/mL
Number of subjects: 78
Study 9085953 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (HM) 0.075 mg/mL
Number of subjects: 78
Study 8280544 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 2.5 mg in saline 10 ml
Number of subjects: 45
Study 8280544 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 2.5 mg in 1:200,000 adrenaline 10 ml
Number of subjects: 45
Study 8280544 — intervention group
Group type: COMPARATOR
Intervention: Saline 10 ml (Control)
Number of subjects: 45
Study 3551972 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD consolidation with monthly maintenance chemotherapy
Number of subjects: 0
Study 3551972 — intervention group
Group type: COMPARATOR
Intervention: TAD consolidation without monthly maintenance chemotherapy
Number of subjects: 0
Study 31317471 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/day selenium supplements as selenium yeast
Number of subjects: 36
Study 31317471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30291841 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing intervention with health messages regarding antenatal care, presented through songs and dances, and supported by a wall chart with key health messages.
Number of subjects: 1510
Study 30291841 — intervention group
Group type: COMPARATOR
Intervention: Control group with no significant intervention.
Number of subjects: 1510
Study 30291841 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing intervention among the most illiterate members of the community.
Number of subjects: 1510
Study 30291841 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up at 12 months.
Number of subjects: 1510
Study 27484082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive steroid (triamcinolone acetonide) given at the time of surgery (4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml sub‐Tenon's).
Number of subjects: 300
Study 27484082 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment and care (control group).
Number of subjects: 300
Study 23842630 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty
Number of subjects: 37
Study 23842630 — intervention group
Group type: COMPARATOR
Intervention: Conventional jig-assisted total knee replacement
Number of subjects: 37
Study 23842630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Computer-assisted and Conventional jig-assisted)
Number of subjects: 37
Study 23867415 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized resting mitt splint
Number of subjects: 10
Study 23867415 — intervention group
Group type: COMPARATOR
Intervention: No splint
Number of subjects: 10
Study 20626379 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended buprenorphine-naloxone (BUP) treatment
Number of subjects: 152
Study 20626379 — intervention group
Group type: COMPARATOR
Intervention: Brief detoxification treatment (DETOX)
Number of subjects: 152
Study 18058832 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Number of subjects: 38
Study 18058832 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Number of subjects: 38
Study 16822654 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided measurement of psoriatic lesion area
Number of subjects: 0
Study 16822654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted PASI index
Number of subjects: 0
Study 16822654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12534638 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam administered once daily for 3 weeks or 6 months at doses between 7.5 and 60 mg
Number of subjects: 586
Study 10375064 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education plus brief counselling intervention
Number of subjects: 264
Study 10375064 — intervention group
Group type: COMPARATOR
Intervention: Health education alone
Number of subjects: 264
Study 8705294 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanotransferrin in brain tissues from AD patients
Number of subjects: 0
Study 8705294 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin receptor in brain tissues from AD patients
Number of subjects: 0
Study 8705294 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin in brain tissues from AD patients
Number of subjects: 0
Study 1866045 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 0
Study 1866045 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study 6897039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral molsidomine 4 mg
Number of subjects: 10
Study 6897039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 10
Study 31733647 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 353
Study 31733647 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 353
Study 30006977 — intervention group
Group type: EXPERIMENTAL
Intervention: Light microscopy using knizocyte visual cue
Number of subjects: 971
Study 30006977 — intervention group
Group type: COMPARATOR
Intervention: Standard PCR genotyping
Number of subjects: 971
Study 30006977 — intervention group
Group type: EXPERIMENTAL
Intervention: Light microscopy (generalized mixed modeling)
Number of subjects: 971
Study 30006977 — intervention group
Group type: EXPERIMENTAL
Intervention: Light microscopy excluding error-prone reader
Number of subjects: 971
Study 26818127 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsules (XFC), 3 pills three times daily for 2 months
Number of subjects: 80
Study 26818127 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium glycoside (TPT), 2 pills three times daily for 2 months
Number of subjects: 80
Study 24636358 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 sessions of a group-based, community-participative, psychosocial intervention (n=79)
Number of subjects: 159
Study 24636358 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=80)
Number of subjects: 159
Study 22059409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of selected lactobacilli up to the 24th to 26th week of gestation
Number of subjects: 644
Study 22059409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study 19037804 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (15 mg/person)
Number of subjects: 16
Study 19037804 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (30 mg/person)
Number of subjects: 16
Study 19037804 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (15 or 30 mg/person)
Number of subjects: 16
Study 19037804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16935685 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol (160 microg and 4.5 microg)
Number of subjects: 3394
Study 16935685 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed formoterol (4.5 microg)
Number of subjects: 3394
Study 16935685 — intervention group
Group type: COMPARATOR
Intervention: As-needed terbutaline (0.4 mg)
Number of subjects: 3394
Study 16935685 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 3394
Study 12617263 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (Rebif) treatment
Number of subjects: 38
Study 10871468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose magnesium sulfate (5 g/h)
Number of subjects: 0
Study 10871468 — intervention group
Group type: COMPARATOR
Intervention: Low-dose magnesium sulfate (2 g/h)
Number of subjects: 0
Study 8926389 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (XRT) with hyperthermia (HT)
Number of subjects: 23
Study 8926389 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (XRT) without hyperthermia (HT)
Number of subjects: 23
Study 1393304 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 78
Study 1393304 — intervention group
Group type: EXPERIMENTAL
Intervention: phenelzine
Number of subjects: 78
Study 1393304 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study 4007253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbed tetanus vaccine from source 1
Number of subjects: 197
Study 4007253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbed tetanus vaccine from source 2
Number of subjects: 197
Study 30560427 — intervention group
Group type: EXPERIMENTAL
Intervention: Federal monitoring lotteries program (audited municipalities)
Number of subjects: 1520
Study 30560427 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-audited municipalities)
Number of subjects: 1520
Study 28362661 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard colonoscopy in conjunction with fecal occult blood testing
Number of subjects: 63
Study 28362661 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 63
Study 25912590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 72
Study 25912590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 72
Study 25912590 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 72
Study 23262118 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART‐OP (self‐guided, multimedia stress management and resilience training program)
Number of subjects: 66
Study 23262118 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) group (marketed videos and published material on stress management)
Number of subjects: 66
Study 23262118 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART‐OP
Number of subjects: 66
Study 23262118 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 66
Study 21985278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (7 schools)
Number of subjects: 1348
Study 21985278 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 schools)
Number of subjects: 1348
Study 19157345 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPCEA
Number of subjects: 60
Study 19157345 — intervention group
Group type: COMPARATOR
Intervention: PCEABI
Number of subjects: 60
Study 17082219 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy plus endocrine therapy
Number of subjects: 95
Study 17082219 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy plus endocrine therapy
Number of subjects: 95
Study 15535165 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousing words presented at the periphery during encoding
Number of subjects: 0
Study 15535165 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral words presented at the periphery during encoding
Number of subjects: 0
Study 10912550 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling during antenatal and post-natal period
Number of subjects: 995
Study 10912550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer counselling)
Number of subjects: 995
Study 9162292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemitil (0.5 g)
Number of subjects: 0
Study 9162292 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenibut (0.25 g)
Number of subjects: 0
Study 8243522 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide co-infused with bombesin
Number of subjects: 6
Study 8243522 — intervention group
Group type: COMPARATOR
Intervention: Saline co-infused with bombesin
Number of subjects: 6
Study 3753670 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg nifalatide
Number of subjects: 72
Study 3753670 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mg nifalatide
Number of subjects: 72
Study 3753670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 30721208 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept administered as 1 injection every other month after 3 initial monthly doses
Number of subjects: 0
Study 30721208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Re Nata (PRN) regimen
Number of subjects: 0
Study 30721208 — intervention group
Group type: EXPERIMENTAL
Intervention: Observe-and-Plan (O&P) regimen
Number of subjects: 0
Study 30721208 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat and Extend (T&E) regimen
Number of subjects: 0
Study 27458584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (40 mg) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Number of subjects: 48
Study 27458584 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg IV) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Number of subjects: 48
Study 25525354 — intervention group
Group type: EXPERIMENTAL
Intervention: ELLIPTA® dry powder inhaler
Number of subjects: 150
Study 25525354 — intervention group
Group type: COMPARATOR
Intervention: BREEZHALER™
Number of subjects: 150
Study 22759932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 198
Study 22759932 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 198
Study 19996996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Progressive Resistance Training (HI PRT)
Number of subjects: 1313
Study 19996996 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 1313
Study 19996996 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 1313
Study 18245398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 1202
Study 18245398 — intervention group
Group type: COMPARATOR
Intervention: Serious pulmonary hemorrhage
Number of subjects: 1202
Study 16449409 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 39
Study 16449409 — intervention group
Group type: COMPARATOR
Intervention: Trauma scripts
Number of subjects: 39
Study 12953801 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatinose (5 g)
Number of subjects: 0
Study 12953801 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 0
Study 11029566 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride catheter
Number of subjects: 235
Study 11029566 — intervention group
Group type: COMPARATOR
Intervention: Control catheter (polyurethane non-antiseptic)
Number of subjects: 235
Study 8943171 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 107
Study 8943171 — intervention group
Group type: COMPARATOR
Intervention: Iodide substitution
Number of subjects: 107